Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Saniona AB ( (SE:SANION) ) has shared an announcement.
Saniona reported full-year 2025 revenue of SEK 434.4 million, up from SEK 334.7 million, with operating profit rising to SEK 271.0 million and net profit to SEK 284.6 million, supported by a solid cash position of SEK 580.8 million. However, the fourth quarter showed a sharp revenue drop to SEK 4.6 million and an operating loss of SEK 46.5 million, as the company invests in moving multiple proprietary programs toward the clinic.
The company underscored a strategic shift from partnership validation to disciplined clinical execution, signaling a focus on translating its ion channel expertise into late-stage assets and long-term value creation. New leadership appointments in clinical development, translational medicine, toxicology and CMC are intended to reinforce operational capabilities, positioning Saniona for the next phase of growth and execution for both patients and shareholders.
The most recent analyst rating on (SE:SANION) stock is a Buy with a SEK30.00 price target. To see the full list of analyst forecasts on Saniona AB stock, see the SE:SANION Stock Forecast page.
More about Saniona AB
Saniona AB is a Swedish biopharmaceutical company specializing in ion channel-targeted therapies, aiming to discover, develop and deliver innovative treatments for patients with high unmet medical needs. The company advances proprietary drug programs and pursues collaborations with partners, using these partnerships both to validate its science and to strengthen its financial position.
Average Trading Volume: 974,897
Technical Sentiment Signal: Buy
Current Market Cap: SEK3.2B
See more insights into SANION stock on TipRanks’ Stock Analysis page.